In‐frame triplet deletions in<i>RHD</i>alter the D antigen phenotype
Willy A. Flegel(National Institutes of Health), Franz F. Wagner(DRK-Blutspendedienst Baden-Württemberg - Hessen), Nicole I. Eicher(Biotest (Germany)), Peter Gowland(Swiss Red Cross), Manfred Ernst(Swiss Red Cross), Hubert Schrezenmeier(German Red Cross), Ingeborg Von Zabern(Swiss Red Cross), Hein Hustinx, Andrea Doescher(University of the West of England), Behrouz Mansouri Taleghani(Swiss Red Cross), Eduard K. Petershofen(Swiss Red Cross), Ursula Bauerfeind(Swiss Red Cross)
Cited by 23
Related Papers
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|653
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|578
Molecular Basis of Weak D Phenotypes
|Blood|1999|336
Molecular Basis of Weak D Phenotypes
|Blood|1999|331